Using the latest in nanotechnology, Ipsen has developed a Potential Cure For Pancreatic Cancer. The drug is called Nanoliposomal Irinotecan and if it works, it could be a major breakthrough in the treatment of this deadly disease. It is hoped that the drug will be able to detect the disease earlier, allowing for the development of an effective treatment.
Genetic profiling of advanced pancreatic adenocarcinoma
Using genomic techniques, researchers are able to examine advanced pancreatic adenocarcinoma samples to identify genetic alterations in tumors. These alterations are often predictive biomarkers for treatment. They are also a valuable tool in the search for novel therapeutic approaches. Identifying alterations in tumors has the potential to improve patient outcomes. However, the FDA’s approval process for such tests can be time-consuming and costly.
In the United States, about 60,430 adults will be diagnosed with pancreatic cancer this year. Approximately one-third of these patients will be diagnosed early in the course of their disease. The 5-year survival rate for patients with early-stage PDAC is about 31%. However, there is a high incidence of relapse and resistance to conventional treatment. This is due in part to the pancreatic tumor microenvironment, a highly immunosuppressive environment that plays an important role in the tumorigenesis and development of cancer. In addition, signaling pathways have been implicated in many processes involved in cancer, including cell proliferation, migration, and angiogenesis. Understanding these pathways could provide a foundation for the development of molecularly targeted therapies.
Nanoliposomal irinotecan
Currently, the survival rate for patients with pancreatic cancer is very poor. However, it has been shown that combination therapies can be beneficial in the first line setting. Some of these therapies include gemcitabine/nab-paclitaxel and FOLFIRINOX. In addition, immunotherapies have also been shown to be effective. The use of liposomal irinotecan has the potential to improve the survival rate for patients with pancreatic cancer.
A Phase III study was conducted to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI). The trial was a randomized, double-blind, controlled study to compare nal-IRI+5-fluorouracil (FOLFIRINOX) to 5-fluorouracil/leucovorin (FOL/LV) alone. The study was also used to determine the optimal dose and cycle length for further studies.
The study evaluated patients with mPDAC or locally advanced pancreatic cancer. Eligible patients were required to have a Karnofsky performance status (KPS) of 70 or higher. They must also have adequate hepatic, renal, and haematological function, and have been treated with gemcitabine-based therapy in the past. In addition, they must have measurable lesions. The study also assessed pharmacokinetics.
Precision Promise
Until recently, the clinical development of new pancreatic cancer treatments has been slow, expensive and unsuccessful. However, innovations in clinical trial design have given hope for accelerated progress in the near future. Precision PromiseSM (NCT04229004) is an adaptive clinical trial designed to accelerate the development of new pancreatic cancer treatments. This novel clinical trial platform has the potential to reduce the cost of drug development by up to two years, and may lead to faster approval of new treatments.
Precision Promise SM was created by a national team of leading clinicians and researchers, and is designed to be a central hub for clinical advancement. It will enroll patients with metastatic pancreatic adenocarcinoma, and will be located at over 20 Clinical Trial Consortium sites in the U.S. In addition to enrolling patients, Precision Promise is also designed to facilitate collaboration between scientists and clinicians. This adaptive clinical trial design will also reduce the number of patients needed for testing each new treatment.
The trial’s master protocol includes extensive molecular profiling and sub-studies. This includes PRIMUS, which is a study designed to identify predictive biomarkers for targeted agents, and REVOLUTION, which tests combination approaches that include immunotherapy. The trial will also include broad-panel genomic testing. This will enable researchers to understand the molecular underpinnings of pancreatic adenocarcinoma. This will aid researchers in designing more targeted treatments.
Surgical resection is the only chance of a cure
Surgical resection is the only known treatment for pancreatic cancer that is able to cure the disease. However, the treatment option is currently only used for about 20% of patients with pancreatic cancer. This is because the disease often progresses, and surgeons may not be able to remove all of the cancer.
In this study, postoperative survival rates were compared for elderly patients with resectable pancreatic cancer who received surgery and those who did not. The results were published in the Annals of Surgery in 2021. In this study, 49 patients with resectable pancreatic tumors were enrolled. The median age was 78 years. The majority of patients had stage 3 disease, but the study also included patients with stage 4 cancer.
After undergoing surgery, the patients received adjuvant chemotherapy. The chemotherapy regimen included modified folinic acid, fluorouracil and oxaliplatin. The chemotherapy was given based on the patient’s tolerance. Adjuvant chemotherapy is an important component of treatment for resectable pancreatic cancer. Studies have shown that this treatment can prolong survival, and the chance of cancer returning is decreased. However, only 50 percent of patients are able to receive this treatment because of comorbidities and complications.
Read More News at Life Sciences Voice
